Overview
The FDA Expanded Access program (compassionate use) provides a regulatory pathway for Havana Syndrome patients to access investigational peptide treatments when conventional options have failed. This framework exists specifically for serious conditions lacking adequate treatments.
Eligibility Criteria
Patients must meet all four criteria:
1. Serious or life-threatening condition — Havana Syndrome symptoms include cognitive dysfunction, persistent anxiety, sleep disturbances, and neurological deficits that significantly impair daily functioning
2. No satisfactory alternatives — Conventional treatments (methylphenidate for dopamine, benzodiazepines for anxiety, sleep medications) provide only symptomatic management without addressing root causes like neuroinflammation or BDNF depletion
3. Unable to participate in clinical trials — No FDA-approved clinical trials exist for Khavinson peptides; Russian studies cannot serve as Western validation
4. Potential benefit justifies risks — Safety profile across 15 million patients over four decades demonstrates favorable risk-benefit ratio
Practical Barriers
| Barrier | Status |
|---------|--------|
| U.S. Manufacturers | None currently produce Khavinson peptides |
| Quality Verification | Challenging for imported products |
| Insurance Coverage | Rarely covers investigational treatments |
| FDA Approval Rate | 99% approval rate for compassionate use applications |
Regulatory Process
1. Physician submits expanded access application to FDA with comprehensive scientific rationale
2. FDA reviews safety data (existing Russian studies, acute toxicity at 5,000× doses)
3. Application approved if criteria met; treatment proceeds under monitoring
4. Patient receives peptides intranasally for optimal brain delivery
Related Pages
khavinson-peptides-havana-syndrome — Detailed overview of peptide mechanisms and clinical applications
neurological-effects-of-microwaves — Comprehensive review of neural responses to microwave exposure including behavioral changes, cellular effects, and pharmacological analyses